Drug class

Thalidomide and Derivative Immunomodulators

Thalidomide and derivative immunomodulators, commonly referred to as immunomodulatory drugs (IMiDs), are a distinct class of synthetic oral compounds that modify immune system activity, inhibit angiogenesis, and exert direct antiproliferative and cytotoxic effects against malignant cells. Read more about Thalidomide and Derivative Immunomodulators

30 drugs in this class 21 manufacturers

Advertisement

Drugs in Thalidomide and Derivative Immunomodulators

Showing 10–18 of 30 drugs

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
SUN PHARMACEUTI

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
AUROBINDO PHARM

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
CIPLA USA, INC.

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
BIOCON PHARMA I

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
ZYDUS PHARMACEU

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
EXELAN PHARMACE

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
NOVUGEN PHARMA

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
Padagis US

LENALIDOMIDE

THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS · MULTIPLE MYELOMA ·+6
ACCORD HEALTHCA
Filter & compare in the drug finder → Opens the drug finder with Thalidomide and Derivative Immunomodulators preselected. Add indication or manufacturer filters there.

About Thalidomide and Derivative Immunomodulators.

Thalidomide and derivative immunomodulators, commonly referred to as immunomodulatory drugs (IMiDs), are a distinct class of synthetic oral compounds that modify immune system activity, inhibit angiogenesis, and exert direct antiproliferative and cytotoxic effects against malignant cells.

These agents, which include thalidomide and its analogues lenalidomide and pomalidomide, primarily function by binding the E3 ubiquitin ligase component cereblon (CRBN), prompting the targeted ubiquitination and proteasomal degradation of critical lymphoid transcription factors.

Therapeutically, this drug class is predominantly employed in hematologic oncology to treat multiple myeloma and myelodysplastic syndromes, as well as in dermatologic manifestations of inflammatory conditions such as erythema nodosum leprosum.